×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lymphoma

Kristie L. Kahl
Patients with blood cancers typically value time spent at home in their end-of-life care, however, health care systemts do not always prioritize this in their own quality measures.
Kristie L. Kahl
Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.
Kim Johnson
From diagnosis to remission, my sister had cancer for nearly three years. Because of that, the cancer dates that mark my calendar are plentiful. I can recall most of them from memory without a second glance. While I was recently going through my old planners, I noticed just how many dates are filled with notations of cancer.
Jason Harris
Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat adult and pediatric patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).
Kim Johnson
Treatment decisions are not always easy, but this is one I don't regret making.
Kim Johnson
Cancer treatment isn't what it used to be, and it is important that patients and their loved ones understand that.
Ryan Hamner
I know I’ll never be Thor, but I do know the best way to ingest fungus.
The Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the drug.
Chelsea LoCascio
While recent advances in hematology are exciting, they open the door to more questions.
Jason M. Broderick
A new drug was approved for patients with cutaneous T-cell lymphoma (CTCL). 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable